T. Rowe Price Associates
HBIO icon

T. Rowe Price Associates’s Harvard Bioscience HBIO Stock Holding History

T. Rowe Price Associates’s Portfolio HBIO Stock Details HBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,262
Closed -$8K – 3092
2025
Q1 		$8K Hold
1,262
– – ﹤0.01% 3025
2024
Q4 		$27K Hold
1,262
– – ﹤0.01% 2982
2024
Q3 		$34K Hold
1,262
– – ﹤0.01% 2966
2024
Q2 		$36K Hold
1,262
– – ﹤0.01% 2885
2024
Q1 		$54K Buy
+1,262
New +$56.7K ﹤0.01% 2864
2017
Q4 		– Sell
-2,820
Closed -$106K – 2585
2017
Q3 		$106K Hold
2,820
– – ﹤0.01% 2492
2017
Q2 		$72K Hold
2,820
– – ﹤0.01% 2509
2017
Q1 		$73K Hold
2,820
– – ﹤0.01% 2515
2016
Q4 		$86K Hold
2,820
– – ﹤0.01% 2480
2016
Q3 		$77K Hold
2,820
– – ﹤0.01% 2470
2016
Q2 		$81K Sell
2,820
-10
-0.4% -$318 ﹤0.01% 2450
2016
Q1 		$85K Hold
2,830
– – ﹤0.01% 2430
2015
Q4 		$98K Buy
2,830
+10
+0.4% +$342 ﹤0.01% 2427
2015
Q3 		$107K Hold
2,820
– – ﹤0.01% 2398
2015
Q2 		$161K Hold
2,820
– – ﹤0.01% 2393
2015
Q1 		$164K Buy
2,820
+1,390
+97% +$74.7K ﹤0.01% 2396
2014
Q4 		$81K Hold
1,430
– – ﹤0.01% 2487
2014
Q3 		$58K Hold
1,430
– – ﹤0.01% 2510
2014
Q2 		$65K Buy
1,430
+250
+21% +$10.5K ﹤0.01% 2498
2014
Q1 		$56K Hold
1,180
– – ﹤0.01% 2474
2013
Q4 		$55K Sell
1,180
-245
-17% -$10.7K ﹤0.01% 2452
2013
Q3 		$57K Hold
1,425
– – ﹤0.01% 2427
2013
Q2 		$51K Buy
+1,425
New +$54.6K ﹤0.01% 2396

Other funds holding HBIO

AE
AMH Equity Great Neck, New York $80.3M AUM 78.34% 1-Year Est. Return
HP
Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
MIM
Meros Investment Management Dallas, Texas $231M AUM 35.94% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

T. Rowe Price Associates's HBIO Position: Q2 2025 in Review

T. Rowe Price Associates sold out of Harvard Bioscience (HBIO) in Q2 2025, closing a stake of 1,262 shares — an estimated $8K sold.

T. Rowe Price Associates first reported a position in HBIO in Q2 2013 and held it in 23 quarters. The position peaked at $164K in Q1 2015. 68 funds tracked by Wall St. Rank hold HBIO as of Q2 2025.

  • T. Rowe Price Associates reported no remaining Harvard Bioscience position as of Q2 2025 after selling out during the quarter.
  • T. Rowe Price Associates sold 1,262 Harvard Bioscience shares in Q2 2025, an estimated $8K.
  • T. Rowe Price Associates first reported a position in Harvard Bioscience in Q2 2013 and held it in 23 quarters.
  • T. Rowe Price Associates's Harvard Bioscience position peaked at $164K in Q1 2015.
  • 68 funds tracked by Wall St. Rank held Harvard Bioscience as of Q2 2025.

Based on T. Rowe Price Associates's 13F filing for Q2 2025, filed 14 Aug 2025.